Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSCN1 | Q16658 | 1/20 | 0.66 |
| ▸ | PTGER4 | P35408 | 9/20 | 0.51 |
| ▸ | CPT1A | P50416 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17038823 | 1.00 | FSCN1 (0.66) | FSCN1PTGER4CPT1ANR3C1ADORA3 | |
| SCHEMBL17199348 | 0.89 | FSCN1 (0.51) | FSCN1PTGER4CPT1AHDAC3HDAC1 | |
| SCHEMBL21662154 | 0.88 | FSCN1 (0.53) | FSCN1PTGER4CPT1ANR3C1ADORA3 | |
| SCHEMBL17038824 | 0.86 | FSCN1 (0.66) | FSCN1PTGER4CPT1AADORA3HDAC3 | |
| SCHEMBL30695006 | 0.86 | FSCN1 (0.66) | FSCN1PTGER4CPT1AADORA3HDAC3 | |
| SCHEMBL30501125 | 0.86 | FSCN1 (0.70) | FSCN1PTGER4CPT1ANR3C1ADORA3 | |
| SCHEMBL17038973 | 0.86 | FSCN1 (0.70) | FSCN1PTGER4CPT1ANR3C1ADORA3 | |
| SCHEMBL17038827 | 0.85 | FSCN1 (0.69) | FSCN1PTGER4CPT1AADORA3 | |
| SCHEMBL30501120 | 0.85 | FSCN1 (0.69) | FSCN1PTGER4CPT1AADORA3 | |
| SCHEMBL30695042 | 0.85 | FSCN1 (0.66) | FSCN1PTGER4CPT1AADORA3HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333411-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY (US) | 2025-10-30 | — | — | US | disclosed |
| US-12168658-B2 | Compounds and methods for inhibiting fascin | NOVITA PHARMACEUTICALS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | CORNELL UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124449-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | FSCN1 1/4885PTGER4 4107/4885CPT1A 117/4885 |
| US-20250333411-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | FSCN1 1/4885PTGER4 4107/4885CPT1A 117/4885 |
| US-11858929-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | FSCN1 1/4885PTGER4 4107/4885CPT1A 117/4885 |
| US-12168658-B2 | Compounds and methods for inhibiting fascin | FSCN1, MTPN, MYOF | FSCN1 1/4885PTGER4 4107/4885CPT1A 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.